How is severe or critical coronavirus disease 2019 (COVID-19) managed?

Answer

Not all patients with coronavirus disease 2019 (COVID-19) will require medical supportive care. Clinical management for hospitalized patients with COVID-19 is focused on supportive care of complications, including advanced organ support for respiratory failure, septic shock, and multiorgan failure. Empiric testing and treatment for other viral or bacterial etiologies may be warranted.^[10]

Patients with severe or critical COVID-19 are likely to require aerosol-generating procedures, so they should be placed in an airborne infection isolation room (AIIR), if available.

Supplemental oxygen therapy should immediately be administered to patients with severe COVID-19 who have severe acute respiratory infection (SARI) and respiratory distress, hypoxemia, or shock, with the peripheral oxygen saturation target being greater than 94%.^[4]

Patients with severe COVID-19 should be closely monitored for signs of clinical deterioration (eg, rapidly progressive respiratory failure and sepsis), with supportive care interventions administered immediately.^[4]

In a case of severe COVID-19, the patient’s comorbid condition(s) should be understood in order to tailor the management of critical illness.^[4]

Fluid management: When shock is not evident, conservative fluid management should be used in patients with SARI.^[4]

Empiric antimicrobial therapy should be administered as soon as possible to treat all likely pathogens causing SARI and sepsis, with such treatment provided within 1 hour of initial evaluation for patients with sepsis.^[4]

Severe hypoxemic respiratory failure must be recognized when standard oxygen therapy is failing in a patient with respiratory distress; prepare for administration of advanced oxygen/ventilatory support.^[4]

Remdesivir treatment should be administered to hospitalized patients with severe disease.

Corticosteroids are not routinely recommended for viral pneumonia or acute respiratory distress syndrome (ARDS) and should be avoided unless indicated for another reason (eg, COPD exacerbation, refractory septic shock). Nonetheless, The UK RECOVERY trial showed that low-dose dexamethasone (6 mg PO or IV daily for 10 days) randomized to 2104 patients reduced deaths by 35% in ventilated patients (P = 0.0003) and by 20% in other patients receiving oxygen only (P = 0.0021) compared with patients who received standard of care (n = 4321). No benefit was seen in patients who did not require respiratory intervention (P = 0.14).^[11]

Acute respiratory distress syndrome (ARDS)

Prone ventilation for 12-16 hours per day is recommended in adult mechanically ventilated patients with refractory hypoxemia despite optimized ventilation. ^[4]
Oxygenation for severe ARDS:
- Adults: PaO₂/FiO₂≤100 mm Hg with PEEP ≥5cmH₂0 or nonventilated (When PaO₂ is not available, SpO₂/FiO₂ ≤315 suggests ARDS);
- Children: OI ≥16 or OSI ≥12.3
Cardiologists should prepare to aid other specialists in managing cardiac complications in patients with severe COVID-19. ^[12]

Cardiovascular

Cardiology and critical-care teams should coordinate management of patients requiring extracorporeal circulatory support with veno-venous (V-V) versus veno-arterial (V-A) extracorporeal membrane oxygenation (ECMO). ^[12]
Obtain echocardiography in the setting of heart failure, arrhythmia, electrocardiographic (ECG) changes, or cardiomegaly. ^[12]
It is reasonable to triage patients with COVID-19 according to the presence of underlying cardiovascular, diabetic, respiratory, renal, oncologic, and other chronic diseases for prioritized treatment. ^[12]
Providers are cautioned that classic symptoms and presentation of acute myocardial infarction may be overshadowed in the context of COVID-19, resulting in underdiagnosis. ^[12]

Did this answer your question?

Yes No

Additional feedback? (Optional)

Thank you for your feedback!

CDC. Coronavirus Disease 2019 (COVID-19): Evaluating and Testing PUI. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html. May 3, 2020; Accessed: June 9, 2020.
CDC. Symptoms of Coronavirus. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. May 13, 2020; Accessed: June 26, 2020.
CDC. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. June 2, 2020; Accessed: June 9, 2020.
World Health Organization. Severe Acute Respiratory Infections Treatment Centre. Practical manual to set up and manage a SARI treatment centre and a SARI screening facility in health care facilities. WHO. Available at https://www.who.int/publications-detail/severe-acute-respiratory-infections-treatment-centre. March 2020; Accessed: June 9, 2020.
CDC. Coronavirus Disease 2019 (COVID-19): Caring for Someone Sick at Home. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/care-for-someone.html. May 8, 2020; Accessed: June 9, 2020.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28. 395 (10229):1054-1062. [Medline].
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24. [Medline].
CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. Morbidity and Mortality Weekly Report (MMWR). Available at https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e2.htm. March 31, 2020; Accessed: April 2, 2020.
CDC. Coronavirus Disease 2019 (COVID-19): People With Certain Medical Conditions. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.html. June 25, 2020; Accessed: June 26, 2020.
CDC. Clinical Care Guidance for Healthcare Professionals about Coronavirus (COVID-19). CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care.html. June 1, 2020; Accessed: June 9, 2020.
Horby P, Landray M. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 (RECOVERY Trial). Oxford University News Release. Available at https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf. June 16, 2020; Accessed: June 17, 2020.
American College of Cardiology. ACC clinical bulletin: COVID-19 clinical guidance for the cardiovascular care team. ACC. Available at https://www.acc.org/~/media/665AFA1E710B4B3293138D14BE8D1213.pdf. March 6, 2020; Accessed: June 9, 2020.
[Guideline] Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020 May 22. [Medline].
FDA. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. fda.gov. Available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. May 1, 2020; Accessed: May 1, 2020.
FDA. FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF REMDESIVIR (GS-5734™). fda.gov. Available at https://www.fda.gov/media/137566/download. May 1, 2020; Accessed: May 1, 2020.
Mulangu S, Dodd LE, Davey RT Jr, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019 Dec 12. 381 (24):2293-2303. [Medline].
Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020 Mar 9. [Medline].
Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5. 382 (10):929-936. [Medline].
Remdesivir access program. Gilead Sciences. Available at https://rdvcu.gilead.com/.
National Institutes of Health. NIH clinical trial of remdesivir to treat COVID-19 begins. Department of Health and Human Services. Available at https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins. February 25, 2020; Accessed: March 24, 2020.
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 May 16. 395 (10236):1569-1578. [Medline].
Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 May 27. [Medline].
Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 Apr 10. [Medline].
Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10. 11 (1):222. [Medline].
[Guideline] NIH. Potential Antiviral Drugs Under Evaluation for the treatment of COVID-19. COVID-19 Treatment Guidelines. Available at https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/. June 11, 2020; Accessed: June 17, 2020.
Baden LR, Rubin EJ. Covid-19 - The Search for Effective Therapy. N Engl J Med. 2020 Mar 18. [Medline].
Li Y, Xie Z, Lin W, Cai W, Wen C, Guan Y, et al. Efficacy and safety of lopinavir/ritonavir or Arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Med (from Cell Press). 2020 Apr 17. [Full Text].
Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30. 395 (10238):1695-1704. [Medline].
Ampligen as an antiviral. AIM ImmunoTech. Available at https://b2icontent.irpass.com/2265/180859.pdf. February 2020; Accessed: March 13, 2020.
AIM ImmunoTech's Drug Ampligen to Be Tested by Japan's National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19. AIM ImmunoTech. Available at https://aimimmuno.irpass.com/AIM-ImmunoTechs-Drug-Ampligen-to-Be-Tested-by-Japans-National-Institute-of-Infectious-Diseases-as-a-Potential-Treatment-for-the-New-SARS-Coronavirus-SARS-CoV-2-Responsible-for-the-New-Human-Infectious. March 9, 2020;
PharmaMar reports positive results for Aplidin against coronavirus HCoV-229E. PharmaMar. Available at http://pharmamar.com/wp-content/uploads/2020/03/PR_Results_Aplidin_coronavirus.pdf. March 13, 2020;
Fujifilm to start phase II clinical trial of Avigan for COVID-19 patients in US. Reuters. Available at https://www.reuters.com/article/us-health-coronavirus-fujifilm-avigan/fujifilm-to-start-phase-ii-clinical-trial-of-avigan-for-covid-19-patients-in-u-s-idUSKCN21R0KF. 2020 Apr 09;
Glenmark to commence new phase 3 clinical trial on combination of two anti-viral drugs favipiravir and umifenovir in hospitalized patients of moderate COVID-19 in India. PR Newswire. Available at https://www.prnewswire.com/in/news-releases/glenmark-to-commence-new-phase-3-clinical-trial-on-combination-of-two-anti-viral-drugs-favipiravir-and-umifenovir-in-hospitalized-patients-of-moderate-covid-19-in-india-836904730.html. 2020 May 26;
[Guideline] NIH. Interleukin-6 Inhibitors. COVID-19 Treatment Guidelines. Available at https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/interleukin-6-inhibitors/. June 11, 2020; Accessed: June 16, 2020.
Regeneron and Sanofi Begin Global Kevzara (Sarilumab) Clinical Trial Program in Patients with Severe COVID-19. Regeneron/Sanofi. Available at https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-begin-global-kevzarar-sarilumab-clinical. March 16, 2020;
Regeneron and Sanofi provide update on U.S. phase 2/3 adaptive-designed trial of Kevzara (sarilumab) in hospitalized COVID-19 patients. Regeneron. Available at https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive. 2020 Apr 27;
Genentech initiates phase III clinical trial of Actemra plus remdesivir in hospitalized patients with severe COVID-19 pneumonia. Genentech. Available at https://www.gene.com/media/press-releases/14855/2020-05-27/genentech-initiates-phase-iii-clinical-t. 2020 May 27;
Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. medRxiv. 2020 Jun 03. [Full Text].
Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclaire BA, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients – An observational study19 patients. medRxiv. 2020 May 25. [Full Text].
National Health Commission (NHC) of the People’s Republic of China. The diagnosis and treatment guide of COVID-19 pneumonia caused by new coronavirus infection 7th Edition, published March 3rd, 2020.
Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020 May 5. [Medline].
Tiziana Life Sciences plc to expedite development of its fully human anti-interleukin-6-receptor monoclonal antibody, a potential treatment of certain patients infected with coronavirus COVID-19. Tiziana Life Sciences. Available at https://www.tizianalifesciences.com/news-item?s=2020-03-11-tiziana-life-sciences-plc-to-expedite-development-of-its-fully-human-anti-interleukin-6-receptor-monoclonal-antibody-a-potential-treatment-of-certain-patients-infected-with-coronavirus-covid-19. 2020 Mar 11;
Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun. 2 (6):e325-e331. [Medline].
Huet T, Beaussier H, Voisin O, Jouveshomme S, Daurait Gaelle, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. 2020 May 29. [Full Text].
FDA. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. US Food and Drug Administration. Available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. June 15, 2020; Accessed: June 17, 2020.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar. 30 (3):269-271. [Medline].
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. [Medline].
Horby P, Landray M. Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine. RecoveryTrial.net. Available at https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf. 2020 Jun 05;
FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. US Food & Drug Administration. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or. 2020 Apr 24;
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients. Novartis. Available at https://www.novartis.com/news/media-releases/novartis-sponsor-large-clinical-trial-hydroxychloroquine-hospitalized-covid-19-patients. 2020 Apr 20;
Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 May 7. [Medline].
Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. 2020 Apr 21. [Full Text].
multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12. 43 (3):185-188. [Medline].
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16. 14 (1):72-73. [Medline].
Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial (preprint). MedRxIV. Available at https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2.full.pdf. 2020 Mar 31; Accessed: April 1, 2020.
Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020 Mar. 55 (3):105923. [Medline].
Post-exposure Prophylaxis for SARS-Coronavirus-2. ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT04308668. March 23, 2020; Accessed: March 24, 2020.
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv. 2020 Apr 14. [Full Text].
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20. 105949. [Medline].
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb, Sevestre J, et al. Hydroxychloroquine-Azithromycin and COVID-19. Available at https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf. 2020 Mar 30;
Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020 Jun. 50 (4):384. [Medline].
[Guideline] Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. World Health Organization. Available at https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. 2020 Mar 13; Accessed: March 24, 2020.
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020 Feb 15. 395 (10223):473-475. [Medline].
[Guideline] Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020 Jun. 48 (6):e440-e469. [Medline].
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13. [Medline].
Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, et al. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. medRxiv. 2020 May 05. [Full Text].
Investigational COVID-19 Convalescent Plasma Emergency INDs. US Food and Drug Administration. Available at https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds. 2020 Apr 03; Accessed: April 6, 2020.
Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Apr 1. 130 (4):1545-1548. [Medline].
Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020 Jun 1. 130 (6):2757-2765. [Medline].
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Mar 27. [Medline].
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 28. 117 (17):9490-9496. [Medline].
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020 Jun 3. [Medline].
Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID-19: A matched control study. medRxiv. 2020 May 22. [Full Text].
Chen L, Liu P, Gao H, Sun B, Chao D, Wang F, et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis. 2004 Nov 15. 39 (10):1531-5. [Medline].
Mallinckrodt Supports Investigator-Initiated Study at Massachusetts General Hospital to Assess Effectiveness of Inhaled Nitric Oxide in Patients with Severe Acute Respiratory Distress Syndrome Due to COVID-19. Mallinckrodt plc. Available at http://www.mallinckrodt.com/about/news-and-media/news-detail/?id=26721. 2020 Apr 30;
Bellerophon Therapeutics announces FDA clears initiation of phase 3 study for INOpulse inhaled nitric oxide therapy to treat COVID-19. Bellerophon Therapeutics. Available at http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-announces-fda-clears-initiation-phase-3. 2020 May 11;
CDC. Coronavirus Disease 2019 (COVID-19): Groups at Higher Risk for Severe Illness. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html. May 14, 2020; Accessed: June 9, 2020.
Zhou YH, Qin YY, Lu YQ, Sun F, Yang S, Harypursat V, et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial. Chin Med J (Engl). 2020 Mar 5. [Medline].
Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 Mar 18. [Medline].
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020. 14 (1):58-60. [Medline].
Genentech Initiates Phase III Clinical Trial of Actemra in Hospitalized Patients with Severe COVID-19 Pneumonia. Genentech. Available at https://www.gene.com/media/press-releases/14841/2020-03-18/genentech-initiates-phase-iii-clinical-t. March 18, 2020;
Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012 May 17. 366 (20):1881-90. [Medline].
[Guideline] Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020 Mar 27. [Medline].
FDA News Release. Coronavirus (COVID-19) Update: Daily Roundup, March 24 2020. US Food and Drug Administration. Available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-march-24-2020. March 24, 2020; Accessed: March 26, 2020.
Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19. ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT04290871. March 6, 2020; Accessed: March 13, 2020.
CDC. Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19). Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html. March 17, 2020; Accessed: March 31, 2020.
Medscape Novel Coronavirus (COVID-19) Resource Center. WebMD Inc. Available at https://www.medscape.com/resource/coronavirus. March 2020; Accessed: March 31, 2020.
CDC. Coronavirus Disease 2019 (COVID-19): When You Can be Around Others After You Had or Likely Had COVID-19. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/end-home-isolation.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fprevent-getting-sick%2Fwhen-its-safe.html. May 24, 2020; Accessed: June 9, 2020.
[Guideline] NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. NIH. Available at https://www.covid19treatmentguidelines.nih.gov/. May 12, 2020; Accessed: June 9, 2020.

Media Gallery

of 0

How is severe or critical coronavirus disease 2019 (COVID-19) managed?

Answer

Related Questions:

About

Membership

Apps

WebMD Network

Editions

What to Read Next on Medscape

How is severe or critical coronavirus disease 2019 (COVID-19) managed?

Answer

Related Questions:

References

Tables

Contributor Information and Disclosures

Find Us On

About

Membership

Apps

WebMD Network

Editions

What to Read Next on Medscape

Related Conditions and Diseases

Medscape Consult

News & Perspective

Tools

Slideshow

Most Popular Articles

Recommended